Last reviewed · How we verify

Trimbow pMDI — Competitive Intelligence Brief

Trimbow pMDI (Trimbow pMDI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triple combination inhaler (ICS/LABA/LAMA). Area: Respiratory/Pulmonology.

marketed Triple combination inhaler (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Trimbow pMDI (Trimbow pMDI) — Medicines Evaluation Unit Ltd. Trimbow combines three active ingredients—beclomethasone dipropionate (inhaled corticosteroid), formoterol fumarate (long-acting beta-2 agonist), and glycopyrronium (long-acting muscarinic antagonist)—to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trimbow pMDI TARGET Trimbow pMDI Medicines Evaluation Unit Ltd marketed Triple combination inhaler (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Budesonide/formoterol and tiotropium Budesonide/formoterol and tiotropium Brian J Lipworth marketed Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
BDP/FF/GB BDP/FF/GB Chiesi Farmaceutici S.p.A. phase 3 Triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
BFF MDI (PT009) BFF MDI (PT009) Pearl Therapeutics, Inc. phase 3 Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium Chiesi Farmaceutici S.p.A. phase 3 Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
CHF 5993 100/6/12.5 µg CHF 5993 100/6/12.5 µg Chiesi Farmaceutici S.p.A. phase 3 ICS/LABA/LAMA combination Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Chiesi Farmaceutici S.p.A. phase 3 Triple-combination inhaler (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triple combination inhaler (ICS/LABA/LAMA) class)

  1. Eurofarma Laboratorios S.A. · 1 drug in this class
  2. Medicines Evaluation Unit Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trimbow pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/trimbow-pmdi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: